PDF(Pubmed)
Abstract：
BACKGROUND: Amenamevir is a new anti-varicella-zoster virus drug that inhibits the helicase-primase complex involved in viral replication. Amenamevir has the same effect as valaciclovir on acute pain and skin eruption, but no studies have examined the presence of long-term zoster-associated pain (ZAP) or postherpetic neuralgia (PHN) after amenamevir treatment.
METHODS: A total of 785 herpes zoster patients treated with amenamevir were followed up for 12 months. Patients recorded their pain status on a questionnaire once a month.
RESULTS: The proportion of patients with pain was 20.8% at 90 days, 8.0% at 180 days, 3.8% at 270 days, and 2.7% at 360 days after treatment. The median residual pain duration was 48 days. ZAP resolution rate slowed between 90 and 120 days, suggesting that the main feature of ZAP is a shift from nociceptive pain to neuropathic pain. Older age and more severe skin symptoms at the first visit were associated with a higher risk of developing PHN. Median ZAP duration was high for the head, face, and upper back and chest. Regarding the nature of pain, sudden pain attacks that felt like electric shocks, sensation of numbness, burning sensation, and cold/heat pain tended to remain as PHN.
CONCLUSIONS: Although conclusions must remain tentative without further comparative studies, amenamevir seems to have a similar effect on PHN as conventional nucleoside analogs, despite having a different action mechanism.
BACKGROUND: UMIN000035938.
METHODS: A total of 785 herpes zoster patients treated with amenamevir were followed up for 12 months. Patients recorded their pain status on a questionnaire once a month.
RESULTS: The proportion of patients with pain was 20.8% at 90 days, 8.0% at 180 days, 3.8% at 270 days, and 2.7% at 360 days after treatment. The median residual pain duration was 48 days. ZAP resolution rate slowed between 90 and 120 days, suggesting that the main feature of ZAP is a shift from nociceptive pain to neuropathic pain. Older age and more severe skin symptoms at the first visit were associated with a higher risk of developing PHN. Median ZAP duration was high for the head, face, and upper back and chest. Regarding the nature of pain, sudden pain attacks that felt like electric shocks, sensation of numbness, burning sensation, and cold/heat pain tended to remain as PHN.
CONCLUSIONS: Although conclusions must remain tentative without further comparative studies, amenamevir seems to have a similar effect on PHN as conventional nucleoside analogs, despite having a different action mechanism.
BACKGROUND: UMIN000035938.
摘要：
背景：Amenamevir是一种新型的抗水痘带状疱疹病毒药物，可以抑制参与病毒复制的解旋酶-启动酶复合物。Amenamevir对急性疼痛和皮肤出疹具有与伐昔洛韦相同的作用，但尚未有研究证实阿美那韦治疗后是否存在长期带状疱疹相关性疼痛(ZAP)或带状疱疹后遗神经痛(PHN).
方法：对785例带状疱疹患者进行为期12个月的随访。患者每月一次在问卷上记录他们的疼痛状态。
结果：90天疼痛患者比例为20.8%，在180天时为8.0%，270天的3.8%，治疗后360天，为2.7%。中位残余疼痛持续时间为48天。ZAP分辨率在90到120天之间减慢，表明ZAP的主要特征是从伤害性疼痛转变为神经性疼痛。年龄较大，首次就诊时皮肤症状更严重，发生PHN的风险更高。头部的ZAP持续时间中位数很高，脸,上背部和胸部。关于疼痛的性质，突然的疼痛发作感觉像是电击，麻木的感觉，灼烧感,和冷/热疼痛倾向于保持为PHN。
结论：尽管结论必须保持初步，而无需进一步的比较研究，amenamevir似乎对PHN具有与常规核苷类似物相似的作用，尽管有不同的作用机制。
背景：UMIN000035938.
方法：对785例带状疱疹患者进行为期12个月的随访。患者每月一次在问卷上记录他们的疼痛状态。
结果：90天疼痛患者比例为20.8%，在180天时为8.0%，270天的3.8%，治疗后360天，为2.7%。中位残余疼痛持续时间为48天。ZAP分辨率在90到120天之间减慢，表明ZAP的主要特征是从伤害性疼痛转变为神经性疼痛。年龄较大，首次就诊时皮肤症状更严重，发生PHN的风险更高。头部的ZAP持续时间中位数很高，脸,上背部和胸部。关于疼痛的性质，突然的疼痛发作感觉像是电击，麻木的感觉，灼烧感,和冷/热疼痛倾向于保持为PHN。
结论：尽管结论必须保持初步，而无需进一步的比较研究，amenamevir似乎对PHN具有与常规核苷类似物相似的作用，尽管有不同的作用机制。
背景：UMIN000035938.
